Search the Newsreel

AbbVie (ABBV) Stock May Trade At A Premium Despite Cash Flow Upside

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AbbVie stock has delivered a strong 152.2% return over the past 5 years, yet the valuation signals are split, with a Discounted Cash Flow (DCF) intrinsic value …

AbbVie (ABBV) Stock May Be 45% Undervalued On Raised 2026 Outlook

2 Reasons to Like ABBV and 1 to Stay Skeptical

2 Reasons to Like ABBV and 1 to Stay Skeptical AbbVie has followed the market's trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 9.7% to $249.64 per share while the index has gained …

Die AbbVie-Aktie legt nach starkem Q2-2026-Bericht und angehobener Prognose zu

Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?

AbbVie's neuroscience franchise experienced strong growth in the first half of 2026, with sales reaching $6.1 billion, driven by key drugs like Vraylar, Ubrelvy, Qulipta, and Botox Therapeutic, and the rapid uptake of Vyalev. The company anticipates further growth from the potential approval of …

Thomasville National Bank Buys Shares of 26,575 AbbVie Inc. $ABBV

Thomasville National Bank acquired a new stake of 26,575 shares in AbbVie Inc., valued at approximately $6.687 million, during the second quarter. AbbVie continues to show strong institutional interest, positive analyst sentiment with a "Moderate Buy" consensus and an average price target of $275.50, …

Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?

On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory …

Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?

AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations …

The Sharpest Exchanges From ABBV’s Earnings Call

Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation

Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the …

Wolfe Upgrades AbbVie to Outperform From Peer Perform, Price Target is $300

Wolfe has upgraded AbbVie (ABBV) to an "Outperform" rating from "Peer Perform," setting a new price target of $300. This upgrade indicates a more positive outlook on the pharmaceutical company's stock performance. The article also lists recent news and analyst actions related to AbbVie, …

AbbVie Inc. $ABBV Shares Acquired by Mission Wealth Management LP

Mission Wealth Management LP significantly increased its stake in AbbVie Inc. (NYSE:ABBV) by 119.1% in the second quarter, now holding 69,052 shares valued at $17.4 million. This move is part of a broader trend of institutional investors and hedge funds holding 70.23% of AbbVie's …

How ABBV Stock Moved Away From Its Peer Group

AbbVie (ABBV) has shown strong fundamental performance with high revenue growth and operating margins, yet its stock returns significantly lag behind peers like Merck and Johnson & Johnson. This disconnect is attributed to the market pricing in future competitive threats to AbbVie's key drug …

Las acciones de AbbVie enfrentan volatilidad con fortaleza en resultados, pero la resistencia sigue siendo clave: análisis semanal

AbbVie Inc. $ABBV Shares Bought by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC increased its stake in AbbVie Inc. (NYSE:ABBV) by 7.5% in the second quarter, bringing its total holdings to 134,579 shares valued at $33.9 million. This comes as AbbVie reported strong quarterly results, beating EPS and revenue estimates, …

BTIG downgrades Apogee Therapeutics stock rating after AbbVie deal

BTIG has downgraded Apogee Therapeutics Inc (NASDAQ:APGE) to Neutral from Buy after shareholders approved the company's acquisition by AbbVie Inc (NYSE:ABBV) for $10.9 billion, or $135.11 per share. This deal, which sees Apogee's stock trading near its 52-week high with a significant return, is …

Cardinal Capital Management Inc. Buys 21,206 Shares of AbbVie Inc. $ABBV

Cardinal Capital Management Inc. increased its stake in AbbVie Inc. by 8.4% during the second quarter, purchasing an additional 21,206 shares to bring its total holdings to 273,719 shares valued at approximately $68.9 million. Institutional investors collectively own 70.23% of ABBV, and analysts maintain …

GODSEY & GIBB, INC's AbbVie Inc(ABBV) Holding History

GODSEY & GIBB, INC holds 74,257.00 shares of AbbVie Inc (ABBV) as of June 30, 2026, valued at $18.69 million, representing 1.53% of their stock portfolio. The firm's initial trade was in Q2 2021, and they have made 9 purchases and 9 sales of …

AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision …

AbbVie (ABBV) Gains On Botox Filing, Is The 9% Discount Still There?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AbbVie (ABBV) is back in focus after Allergan Aesthetics reported that the FDA accepted a supplemental Biologics License Application for Botox Cosmetic targeting masseter muscle prominence in …

AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?

This article compares AbbVie and CVS Health as investment opportunities in 2026, highlighting their distinct business models and risk profiles. AbbVie, a biopharmaceutical giant, is favored for its focused operations and exciting growth trajectory, particularly with its immunology portfolio. CVS Health, an integrated healthcare …

How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?

AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% …

Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices

Updated program delivers simplified savings, greater benefits transparency, and expanded opportunities for practice growth Introduces new rewards opportunities for customer segments, including first-time APP members, growing practices, and long-standing loyal customers IRVINE, Calif., Aug. 11, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today …

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

AbbVie (NYSE: ABBV) is aiming high with its $10.6 billion planned purchase of Apogee Therapeutics (NASDAQ: APGE). The deal, pending regulatory approvals, is expected to close in the third quarter. The move is designed to supplement the pharmaceutical giant's already strong immunology portfolio. However, …

AbbVie Inc. $ABBV Position Cut by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its stake in AbbVie Inc. by 1.4% during the second quarter, selling 19,132 shares and now owning 1,362,464 shares worth $342.85 million. Despite this, AbbVie remains a "Moderate Buy" among analysts, with recent positive news including the acquisition of Apogee …

Carolina Wealth Advisors LLC Purchases 7,626 Shares of AbbVie Inc. $ABBV

Carolina Wealth Advisors LLC increased its stake in AbbVie Inc. by 68.6% in the second quarter, purchasing an additional 7,626 shares and bringing its total holdings to 18,741 shares valued at $4.716 million. Other institutional investors have also adjusted their positions in AbbVie, with …

Pharma giants, including AbbVie, sue to block Illinois drug discount law

Major pharmaceutical companies, including AbbVie, Bristol Myers, and Novartis, have filed a lawsuit to block a new drug discount law in Illinois. The lawsuit challenges the state's 340B law, which aims to provide discounted prescription drugs. This legal action by the pharma giants indicates …

AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth Use

AbbVie's Botox Cosmetic has moved closer to FDA approval for a fifth aesthetic use: treating masseter muscle prominence. This potential approval is based on positive Phase 3 study results and aligns with AbbVie's strategy of expanding existing drug indications. While the company shows strong …

AbbVie, Novartis Sue Illinois Over Hospital Drug Pharmacy Law

AbbVie and Novartis AG have filed separate lawsuits against the state of Illinois, challenging a new law that regulates drugmakers' contractual agreements with pharmacies under a federal drug discount program. AbbVie claims the law violates its constitutional property rights by mandating the transfer of …

Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?

AbbVie Stock After the Apogee Financing: What $10 Billion in Notes Signals.

AbbVie recently issued $10 billion in senior notes to finance its $10.9 billion acquisition of Apogee Therapeutics, with the deal expected to close on August 18. Despite narrowing full-year guidance due to acquisition-related dilution, AbbVie reported strong Q2 earnings driven by Skyrizi and Rinvoq …

AbbVie to Acquire Apogee Therapeutics for $10.9 Billion; Apogee Reports Positive Phase 2 Zumilokibart Data and Q2 2026 Results

AbbVie plans to acquire Apogee Therapeutics for $10.9 billion, or $135.11 per share, to bolster its immunology portfolio. This acquisition follows Apogee's positive Phase 2 results for zumilokibart in atopic dermatitis and a $1.3 billion financing deal with Blackstone Life Sciences. The deal is …

Apogee's Atopic Dermatitis Drug Shows 65.9% EASI-75

Apogee Therapeutics announced its Q2 2026 financial results and significant corporate updates, including AbbVie's agreement to acquire the company for approximately $10.9 billion. The acquisition, valued at $135.11 per share in cash, is expected to close in Q3 2026. Additionally, Apogee reported positive Phase …